Forskning ved Københavns Universitet - Københavns Universitet

Forside

Plasma exchange combined with azathioprine in multiple sclerosis using serial gadolinium-enhanced MRI to monitor disease activity: a randomized single-masked cross-over pilot study.

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningfagfællebedømt

Standard

Plasma exchange combined with azathioprine in multiple sclerosis using serial gadolinium-enhanced MRI to monitor disease activity: a randomized single-masked cross-over pilot study. / Sørensen, P.S.; Wanscher, B; Szpirt, W; Jensen, C.V.; Ravnborg, M; Christiansen, P; Schreiber, K; Nordenbo, Annette Mosbæk.

I: Neurology, Bind 46, Nr. 6, 1996, s. 1620-1625.

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningfagfællebedømt

Harvard

Sørensen, PS, Wanscher, B, Szpirt, W, Jensen, CV, Ravnborg, M, Christiansen, P, Schreiber, K & Nordenbo, AM 1996, 'Plasma exchange combined with azathioprine in multiple sclerosis using serial gadolinium-enhanced MRI to monitor disease activity: a randomized single-masked cross-over pilot study.', Neurology, bind 46, nr. 6, s. 1620-1625.

APA

Sørensen, P. S., Wanscher, B., Szpirt, W., Jensen, C. V., Ravnborg, M., Christiansen, P., ... Nordenbo, A. M. (1996). Plasma exchange combined with azathioprine in multiple sclerosis using serial gadolinium-enhanced MRI to monitor disease activity: a randomized single-masked cross-over pilot study. Neurology, 46(6), 1620-1625.

Vancouver

Sørensen PS, Wanscher B, Szpirt W, Jensen CV, Ravnborg M, Christiansen P o.a. Plasma exchange combined with azathioprine in multiple sclerosis using serial gadolinium-enhanced MRI to monitor disease activity: a randomized single-masked cross-over pilot study. Neurology. 1996;46(6):1620-1625.

Author

Sørensen, P.S. ; Wanscher, B ; Szpirt, W ; Jensen, C.V. ; Ravnborg, M ; Christiansen, P ; Schreiber, K ; Nordenbo, Annette Mosbæk. / Plasma exchange combined with azathioprine in multiple sclerosis using serial gadolinium-enhanced MRI to monitor disease activity: a randomized single-masked cross-over pilot study. I: Neurology. 1996 ; Bind 46, Nr. 6. s. 1620-1625.

Bibtex

@article{db4a660a281c4ba1ad92ffb8ca3375c4,
title = "Plasma exchange combined with azathioprine in multiple sclerosis using serial gadolinium-enhanced MRI to monitor disease activity: a randomized single-masked cross-over pilot study.",
abstract = "We enrolled 11 patients with secondary progressive MS in a randomized single-masked cross-over study of plasma exchange (PE) in combination with azathioprine 2 mg/kg. PE was performed once a week for 4 weeks and thereafter every second week for 20 weeks (14 treatments). Eight patients completed the whole trial, and three patients discontinued the trial, two during the run-in period of azathioprine treatment and one at the introduction of PE. The primary efficacy variables were the number of gadolinium-enhancing lesions and the occurrence of new enhancing lesions on serial MRI performed every 3 weeks during the PE and the control period. Secondary efficacy variables were the total MS lesion load on T2-weighted MRI, multimodal evoked potentials, and clinical neurologic ratings. No significant differences were found regarding the number of enhancing lesions or occurrence of new enhancing lesions in the two periods. Although the total MS lesion load on MRI was significantly lower (p < 0.02) and central motor conduction times decreased significantly (p < 0.05) during PE, this small study did not provide sufficient evidence for a significant beneficial effect of PE or encourage a subsequent large randomized parallel group study",
author = "P.S. S{\o}rensen and B Wanscher and W Szpirt and C.V. Jensen and M Ravnborg and P Christiansen and K Schreiber and Nordenbo, {Annette Mosb{\ae}k}",
year = "1996",
language = "English",
volume = "46",
pages = "1620--1625",
journal = "Neurology",
issn = "0028-3878",
publisher = "Lippincott Williams & Wilkins",
number = "6",

}

RIS

TY - JOUR

T1 - Plasma exchange combined with azathioprine in multiple sclerosis using serial gadolinium-enhanced MRI to monitor disease activity: a randomized single-masked cross-over pilot study.

AU - Sørensen, P.S.

AU - Wanscher, B

AU - Szpirt, W

AU - Jensen, C.V.

AU - Ravnborg, M

AU - Christiansen, P

AU - Schreiber, K

AU - Nordenbo, Annette Mosbæk

PY - 1996

Y1 - 1996

N2 - We enrolled 11 patients with secondary progressive MS in a randomized single-masked cross-over study of plasma exchange (PE) in combination with azathioprine 2 mg/kg. PE was performed once a week for 4 weeks and thereafter every second week for 20 weeks (14 treatments). Eight patients completed the whole trial, and three patients discontinued the trial, two during the run-in period of azathioprine treatment and one at the introduction of PE. The primary efficacy variables were the number of gadolinium-enhancing lesions and the occurrence of new enhancing lesions on serial MRI performed every 3 weeks during the PE and the control period. Secondary efficacy variables were the total MS lesion load on T2-weighted MRI, multimodal evoked potentials, and clinical neurologic ratings. No significant differences were found regarding the number of enhancing lesions or occurrence of new enhancing lesions in the two periods. Although the total MS lesion load on MRI was significantly lower (p < 0.02) and central motor conduction times decreased significantly (p < 0.05) during PE, this small study did not provide sufficient evidence for a significant beneficial effect of PE or encourage a subsequent large randomized parallel group study

AB - We enrolled 11 patients with secondary progressive MS in a randomized single-masked cross-over study of plasma exchange (PE) in combination with azathioprine 2 mg/kg. PE was performed once a week for 4 weeks and thereafter every second week for 20 weeks (14 treatments). Eight patients completed the whole trial, and three patients discontinued the trial, two during the run-in period of azathioprine treatment and one at the introduction of PE. The primary efficacy variables were the number of gadolinium-enhancing lesions and the occurrence of new enhancing lesions on serial MRI performed every 3 weeks during the PE and the control period. Secondary efficacy variables were the total MS lesion load on T2-weighted MRI, multimodal evoked potentials, and clinical neurologic ratings. No significant differences were found regarding the number of enhancing lesions or occurrence of new enhancing lesions in the two periods. Although the total MS lesion load on MRI was significantly lower (p < 0.02) and central motor conduction times decreased significantly (p < 0.05) during PE, this small study did not provide sufficient evidence for a significant beneficial effect of PE or encourage a subsequent large randomized parallel group study

M3 - Journal article

VL - 46

SP - 1620

EP - 1625

JO - Neurology

JF - Neurology

SN - 0028-3878

IS - 6

ER -

ID: 34055869